Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)

NCT04612751 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04612751
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04612751 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multicenter, 2-Part, Open-Label Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Immunotherapy With or Without Carboplatin in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (Tropion-Lung04)
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Active, not recruiting
Start date
February 2, 2021
Completion date
May 4, 2027
Enrollment
155 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

advanced or metastatic nsclc